FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912161537> ?p ?o ?g. }

• W2912161537 endingPage "3867" @default.
• W2912161537 startingPage "3859" @default.
• W2912161537 abstract "The aim of this study was to investigate the optimal use of antiresorptive therapy in patients with metastatic cancer in terms of time to treatment initiation, switching strategy in case of skeletal-related event (SRE) or skeletal disease progression, and treatment efficacy beyond 2 years. We conducted a single-center retrospective cohort study including consecutive cancer patients with bone metastases that have received antiresorptive treatment between 2009 and 2015. The outcomes of interest were the time to first and subsequent symptomatic skeletal event (SSE), the skeletal morbidity rate, and the incidence of antiresorptive therapy-specific adverse events depending on the research question. In total, 255 patients included in our study cohort. The time to treatment initiation (direct (n = 143 patients) vs. delayed (n = 87 patients) defined as > 3 months after diagnosis of bone metastases) was not found to influence the time to SSE in (hazard ratio (HR) 0.93; 95% confidence interval (CI) 0.65–1.34) with comparable toxicity. Switching strategy after first SRE or due to skeletal disease progression from bisphosphonates to denosumab was independently associated with longer time to SRE (HR 0.47, 95% CI 0.25–0.88, p value = 0.019) compared with continuation with the same bisphosphonate. Using the landmark approach at 24 months and including 121 patients that survived for more than 2 years, we found that treatment continuation beyond 2 years was associated with longer time to first SSE after 2 years (HR 0.41; 95% CI 0.19–0.93). Our hypothesis-generating results support a more individualized approach on antiresorptive treatment including the lack of detrimental effect when the treatment is delayed, the potential benefit of switching strategy after skeletal disease progression or SSE, and the benefit of continuing antiresorptive treatment beyond 2 years." @default.
• W2912161537 created "2019-02-21" @default.
• W2912161537 creator A5023397484 @default.
• W2912161537 creator A5056394164 @default.
• W2912161537 creator A5071953553 @default.
• W2912161537 date "2019-02-13" @default.
• W2912161537 modified "2023-09-26" @default.
• W2912161537 title "Optimizing antiresorptive treatment in patients with bone metastases: time to initiation, switching strategies, and treatment duration" @default.
• W2912161537 cites W1966063111 @default.
• W2912161537 cites W1975881851 @default.
• W2912161537 cites W2037064486 @default.
• W2912161537 cites W2048420147 @default.
• W2912161537 cites W2054203791 @default.
• W2912161537 cites W2054216838 @default.
• W2912161537 cites W2061202924 @default.
• W2912161537 cites W2072518464 @default.
• W2912161537 cites W2100207941 @default.
• W2912161537 cites W2103904089 @default.
• W2912161537 cites W2112950162 @default.
• W2912161537 cites W2125035379 @default.
• W2912161537 cites W2137458001 @default.
• W2912161537 cites W2139358843 @default.
• W2912161537 cites W2152409486 @default.
• W2912161537 cites W2161962336 @default.
• W2912161537 cites W2170309090 @default.
• W2912161537 cites W2212321276 @default.
• W2912161537 cites W2272748788 @default.
• W2912161537 cites W2308152342 @default.
• W2912161537 cites W2466529557 @default.
• W2912161537 cites W2466759305 @default.
• W2912161537 cites W2562306819 @default.
• W2912161537 cites W2581286732 @default.
• W2912161537 cites W2616966528 @default.
• W2912161537 cites W2787893500 @default.
• W2912161537 cites W4247361750 @default.
• W2912161537 doi "https://doi.org/10.1007/s00520-019-04676-6" @default.
• W2912161537 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6726664" @default.
• W2912161537 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30759277" @default.
• W2912161537 hasPublicationYear "2019" @default.
• W2912161537 type Work @default.
• W2912161537 sameAs 2912161537 @default.
• W2912161537 citedByCount "12" @default.
• W2912161537 countsByYear W29121615372020 @default.
• W2912161537 countsByYear W29121615372021 @default.
• W2912161537 countsByYear W29121615372022 @default.
• W2912161537 countsByYear W29121615372023 @default.
• W2912161537 crossrefType "journal-article" @default.
• W2912161537 hasAuthorship W2912161537A5023397484 @default.
• W2912161537 hasAuthorship W2912161537A5056394164 @default.
• W2912161537 hasAuthorship W2912161537A5071953553 @default.
• W2912161537 hasBestOaLocation W29121615371 @default.
• W2912161537 hasConcept C120665830 @default.
• W2912161537 hasConcept C121332964 @default.
• W2912161537 hasConcept C126322002 @default.
• W2912161537 hasConcept C141071460 @default.
• W2912161537 hasConcept C143998085 @default.
• W2912161537 hasConcept C167135981 @default.
• W2912161537 hasConcept C197934379 @default.
• W2912161537 hasConcept C207103383 @default.
• W2912161537 hasConcept C2776286101 @default.
• W2912161537 hasConcept C2776326535 @default.
• W2912161537 hasConcept C2776541429 @default.
• W2912161537 hasConcept C2777251235 @default.
• W2912161537 hasConcept C44249647 @default.
• W2912161537 hasConcept C61511704 @default.
• W2912161537 hasConcept C71924100 @default.
• W2912161537 hasConcept C72563966 @default.
• W2912161537 hasConceptScore W2912161537C120665830 @default.
• W2912161537 hasConceptScore W2912161537C121332964 @default.
• W2912161537 hasConceptScore W2912161537C126322002 @default.
• W2912161537 hasConceptScore W2912161537C141071460 @default.
• W2912161537 hasConceptScore W2912161537C143998085 @default.
• W2912161537 hasConceptScore W2912161537C167135981 @default.
• W2912161537 hasConceptScore W2912161537C197934379 @default.
• W2912161537 hasConceptScore W2912161537C207103383 @default.
• W2912161537 hasConceptScore W2912161537C2776286101 @default.
• W2912161537 hasConceptScore W2912161537C2776326535 @default.
• W2912161537 hasConceptScore W2912161537C2776541429 @default.
• W2912161537 hasConceptScore W2912161537C2777251235 @default.
• W2912161537 hasConceptScore W2912161537C44249647 @default.
• W2912161537 hasConceptScore W2912161537C61511704 @default.
• W2912161537 hasConceptScore W2912161537C71924100 @default.
• W2912161537 hasConceptScore W2912161537C72563966 @default.
• W2912161537 hasFunder F4320321975 @default.
• W2912161537 hasIssue "10" @default.
• W2912161537 hasLocation W29121615371 @default.
• W2912161537 hasLocation W29121615372 @default.
• W2912161537 hasLocation W29121615373 @default.
• W2912161537 hasLocation W29121615374 @default.
• W2912161537 hasOpenAccess W2912161537 @default.
• W2912161537 hasPrimaryLocation W29121615371 @default.
• W2912161537 hasRelatedWork W2387554703 @default.
• W2912161537 hasRelatedWork W2420443437 @default.
• W2912161537 hasRelatedWork W2909408436 @default.
• W2912161537 hasRelatedWork W3173723023 @default.
• W2912161537 hasRelatedWork W4295367473 @default.
• W2912161537 hasRelatedWork W4311615640 @default.
• W2912161537 hasRelatedWork W4376453587 @default.

• next